title: Neurological immune-related adverse events of ipilimumab.
abstract: Ipilimumab enhances the T lymphocyte mediated immune response to both tumour cells and healthy tissue, improving survival in patients with metastatic melanoma but also leads to more immune-related adverse events (irAEs) than previously used treatments, such as dacarbazine. We present three patients with neurological irAEs from ipilimumab treatment: hypophysitis, meningitis and Guillain-Barré syndrome. Once an irAE occurs, ipilimumab should be stopped and corticosteroids started. Usually, ipilimumab-induced irAE symptoms improve within days to weeks, but can be life-threatening if unrecognised.
authors.affiliation: Department of Neurology, Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute, Amsterdam, The Netherlands. i.bot@neuro.umcn.nl
authors.forename: Ilja
authors.initials: I
authors.lastname: Bot
authors.forename: Christian U
authors.initials: CU
authors.lastname: Blank
authors.forename: Willem
authors.initials: W
authors.lastname: Boogerd
authors.forename: Dieta
authors.initials: D
authors.lastname: Brandsma
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D060908:CTLA-4 Antigen / Q000276:immunology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000074324:Ipilimumab; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology; D008875:Middle Aged
chemical_list: D000911:Antibodies, Monoclonal; D060908:CTLA-4 Antigen; D007155:Immunologic Factors; D000074324:Ipilimumab
keywords: NEUROONCOLOGY; NEUROPHARMACOLOGY